slide1 n.
Skip this Video
Loading SlideShow in 5 Seconds..
Small Molecules for Better Sight PowerPoint Presentation
Download Presentation
Small Molecules for Better Sight

Loading in 2 Seconds...

play fullscreen
1 / 15

Small Molecules for Better Sight - PowerPoint PPT Presentation

  • Uploaded on

Company Presentation. Company Presentation. March 2013. March 2013. Small Molecules for Better Sight. Forward Looking Statements.

I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
Download Presentation

PowerPoint Slideshow about 'Small Molecules for Better Sight' - bridie

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.

- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript

Company Presentation

Company Presentation

March 2013

March 2013

Small Molecules for Better Sight

forward looking statements
Forward Looking Statements

Please be advised that the information and projections provided in this presentation may include forward-looking statements with respect to plans, projections or future performance of the Company, the occurrence of which involves certain risks and uncertainties and is not under the control of OphthaliX, including, but not limited to, changes in regulatory environment, OphthaliX‘ success in implementing its research, development, sales, marketing and manufacturing plans, protection and validity of patents and other intellectual property rights, the impact of currency exchange rates and the effect of competition by other companies



  • CompanyOphthaliX (OTC: OPLI) is a clinical-stage company focused on the development of ophthalmic drugs
  • TechnologyTargeted therapy (A3 adenosine receptor)
  • DrugCF101 is a small molecule orally bioavailable drug which was exclusively licensed from Can-Fite BioPharma (TASE: CFBI; OTC: CANFY) to OphthaliX for the use in the ophthalmic field, and is currently developed for:

Phase 3



Phase 1

Phase 2

Dry Eye Syndrome



*Preparatory work for a Phase 2


Platform Technology


A3 adenosine receptor (A3AR), over-expressed in inflammatory cells

Drug Product

CF101, an agonist at the A3AR; small orally bioavailable molecule

Mechanism of Action

Anti-inflammatory and neuro-protective effect towards retinal ganglion cells

Therapeutic Index

Excellent safety profile and anti-inflammatory effect demonstrated in Phase 2 clinical studies



For the Treatment of Ophthalmic Diseases

cf101 profile
CF101 – Profile

Chemical Profile

Anti-Inflammatory Effect

  • Broad anti-inflammatory effect demonstrated in pre-clinical pharmacology studies :
  • Rheumatoid Arthritis
  • Osteoarthritis
  • Inflammatory Bowel Disease
  • Uveitis
  • Pulmonary Inflammation
  • Sepsis
  • Highly Selective A3AR Agonist
  • Nucleoside derivative
  • Molecular weight - 510.29
  • Water insoluble
  • Orally bioavailable
  • Half life time – 8-9 hours

Excellent Safety Profile


  • ~1,000 patient experience
  • CF101 is safe and well tolerated
  • No dose-response relationship is evident between CF101 and adverse events
  • low incidence (<2%) of serious AEs and similar across all dose groups including placebo

CF101 for Ophthalmic Diseases – Rational

  • Dry Eye/Uveitis - A3AR agonists have a broad anti-inflammatory effect
  • Demonstrated in pre-clinical pharmacology studies in Rheumatoid arthritis, Osteoarthritis, Inflammatory Bowel Disease, Uveitis, Pulmonary inflammation and Sepsis
  • Glaucoma - A3AR agonists induce neuro-protective effects on retinal ganglion cells
  • Prevention of retinal ganglion cells loss both in vitro and in vivo
cf101 ophthalmic market opportunity
CF101 – Ophthalmic Market Opportunity

1 - GlobalData

  • Dry Eye Syndrome
  • Dry Eye Syndrome market was valued at $1.9 billion in 2010 and
  • Forecasted to reach $2.8 billion by 2017 (1)
  • Glaucoma
  • Glaucoma market was valued at $3 billion in 2010 (1)
  • Uveitis
  • Uveitis market was valued at $0.3 billion in 2010
  • Forecasted to reach $1.6 billion by 2017 (1)

Dry Eye Syndrome

Results of former Phase 2 study


Phase 2 Dry Eye Syndrome:

Successfully Concluded

  • A Phase 2, Randomized, Double-Masked, Placebo-Controlled, Parallel-Group Study of the Safety and Efficacy of Daily CF101 (1 mg) Administered Orally to Patients with Dry Eye Syndrome

Fluorescein staining - Improvement Over Time


End of Dosing

CF101-treated group (blue line) as compared to placebo (pink line) over a 12-weeks dosing period. The difference between the group is clearly apparent and significant (p=0.006). The measurement made at week 14, which is 2 weeks post dosing, shows a clear reduction in effect.

Avni et al. Ophthalmology 2010; 117:1287-93


CF101 for Glaucoma Treatment

IOP decrease documented in the phase II dry eye study led to the initiation of a phase II study utilizing CF101 for the treatment of Glaucoma

IOP (intra ocular pressure) change at week 12 from baseline in the CF101-treated group (left column) was statistically significant decreased. These data led to the conclusion that CF101 may be utilized for the treatment of Glaucoma

IOP (intra ocular pressure) change at week 12 from baseline in the CF101-treated group (left column) was statistically significant decreased.

Avni et al. Ophthalmology 2010; 117:1287-93



Pharmacology Studies

cf101 for the treatment of uveitis pharmacology studies
CF101 for the Treatment of Uveitis: Pharmacology Studies

Anti-inflammatory effect of CF101

Posterior Uveitis

Inhibition of EAU by CF101: fundoscopy. Mice were immunized with a uveitogenic regimen of IRBP and treated with CF101 from Day 7 after immunization. Eyes were examined for disease after pupil dilation under a binocular microscope. Shown are results on Day 20 following immunization.

Bar Yehuda et al, Int J Mol Med. 2011; 28(5):727-3


contact information
Contact Information

OphthaliX Inc.

10 Bareket Street Kiryat Matalon


49170 Israel


For additional information, please contact:

Phil Carlson / Diane Imas

KCSA Strategic Communications /

212-896-1233 / 212-896-1242